<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001277</url>
  </required_header>
  <id_info>
    <org_study_id>910085</org_study_id>
    <secondary_id>91-DK-0085</secondary_id>
    <nct_id>NCT00001277</nct_id>
  </id_info>
  <brief_title>Studies of Elevated Parathyroid Activity</brief_title>
  <official_title>Studies of Hyperparathyroidism and Related Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational Phase: Patients whose parathyroid activity is elevated above normal are&#xD;
      referred to as having hyperparathyroidism. This study will help researchers better understand&#xD;
      the causes of hyperparathyroidism and to evaluate and improve methods for diagnosis and&#xD;
      treatment. Patients diagnosed with or suspected of having hyperparathyroidism will be&#xD;
      selected to participate. In addition, patients with related conditions, such as parathyroid&#xD;
      tumors, will also be selected.&#xD;
&#xD;
      Subjects will be asked to provide blood and urine for testing to confirm their condition.&#xD;
      They will then be surgically treated by removal of the parathyroid gland(s)&#xD;
      (parathyroidectomy). Subjects with parathyroid tumors will undergo several diagnostic tests&#xD;
      to determine the exact location of the tumor as well as the tumor's activity. The tests may&#xD;
      include; ultrasounds, nuclear scanning, CT scans, MRI, and specialized blood testing.&#xD;
&#xD;
      Sometimes parathyroidectomy leads to hypoparathyroidism. Options for treating the patients&#xD;
      after the surgical procedure will also be addressed. Calcium and Vitamin D supplements are&#xD;
      typically the mainstay of post parathyroidectomy therapy. Other potential treatments include&#xD;
      transplanting the parathyroid gland(s) to other areas of the body.&#xD;
&#xD;
      Clinical Trial: An imaging substudy was added to this protocol in 2018. Patients with&#xD;
      multiple endocrine neoplasia type 1 (MEN1) will have 68Gallium-Dotatate Positron Emission&#xD;
      Tomography (PET) - Computed Tomography (CT), 18F-DOPA PET/CT, MRI, and CT scans and the&#xD;
      number of lesions detected by each of these types of scans will be compared.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational: Patients with confirmed or suspected primary hyperparathyroidism or&#xD;
      complications therefrom (such as postoperative hypoparathyroidism) will be admitted for&#xD;
      diagnosis and treatment. The principal diagnostic components are calcium in serum and urine,&#xD;
      parathyroid hormone in serum, and mutation tests on germline or tumor DNA. Patients with&#xD;
      moderate to severe primary hyperparathyroidism will be treated. Treatment will be mainly by&#xD;
      parathyroidectomy. Other options are medications or no intervention. Patients with a&#xD;
      hyperparathyroid syndrome may be managed for their extraparathyroid features. Preoperative&#xD;
      testing to localize parathyroid neoplasm(s) will be used usually and with more extended&#xD;
      methods in cases with prior neck surgery. Preoperative tumor localization tests will be&#xD;
      selected according to clinical indications from the following: ultrasound,&#xD;
      technetium-thallium scan, computerized tomography, magnetic resonance imaging, fine needle&#xD;
      aspiration for parathyroid hormone assay, selective arteriogram, selective venous&#xD;
      catheterization for parathyroid hormone assay. Options for management of postoperative&#xD;
      hypocalcemia include calcium, vitamin D analogs, parathyroid autografts and synthetic&#xD;
      parathyroid hormone. Research specimens may consist of blood or tumors.&#xD;
&#xD;
      Clinical Trial: An imaging substudy was added to this protocol in 2018. Patients with MEN1&#xD;
      will have 68Ga-Dotatate PET/CT, 18F-DOPA PET/CT, MRI, and CT scans and the number of lesions&#xD;
      detected by each of these types of scans will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 1993</start_date>
  <completion_date type="Actual">December 23, 2020</completion_date>
  <primary_completion_date type="Actual">March 11, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type of Hyperparathyroidism</measure>
    <time_frame>First year</time_frame>
    <description>The purpose of this study is to understand the causes of primary hyperparathyroidism, to evaluate and improve methods for diagnosis and treatment, and to provide insight into the mechanisms of normal parathyroid function. Hereditary causes of primary hyperparathyroidism will be characterized. Patients were categorized as follows:&#xD;
MEN1: Diagnosed by demonstration of a germline variant in MEN1 gene or one of the following: a) two of three primary MEN1 manifestations b) one primary MEN1 manifestation with a family member with MEN1.&#xD;
Other familial: Non-MEN1 patients who had a positive family history of hyperparathyroidism suspicious for underlying germline predisposition syndrome.&#xD;
Sporadic: Patients who did not have a positive family history of hyperparathyroidism.&#xD;
Unknown: No data to help categorize the patients in any of the above categories.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Organs With Identified Lesions</measure>
    <time_frame>Days 1-6</time_frame>
    <description>For each organ, agreement between 68Ga-DOTATATE and 18F-DOPA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Lesions Identified</measure>
    <time_frame>Days 1-6</time_frame>
    <description>The total number of lesions identified by each imaging modality</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1553</enrollment>
  <condition>Hyperparathyroidism</condition>
  <condition>Hypercalcemia</condition>
  <condition>Parathyroid Neoplasm</condition>
  <condition>Multiple Endocrine Neoplasia</condition>
  <condition>MEN1</condition>
  <arm_group>
    <arm_group_label>Primary hyperparathyroidism</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with confirmed or suspected primary hyperparathyroidism or complications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOTATATE and F-DOPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-Dotatate</intervention_name>
    <description>68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.</description>
    <arm_group_label>DOTATATE and F-DOPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-DOPA</intervention_name>
    <description>18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.</description>
    <arm_group_label>DOTATATE and F-DOPA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Patients who have genetically confirmed MEN1 or clinical criteria of MEN1.&#xD;
&#xD;
          -  For females: Negative urine pregnancy test OR post-menopausal for at least 2 years OR&#xD;
             patient has had a hysterectomy&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Serious underlying medical conditions that restrict diagnostic testing or therapy such&#xD;
             as renal failure or congestive cardiac failure&#xD;
&#xD;
          -  Patients unable or unwilling to give informed consent&#xD;
&#xD;
          -  Pregnant or lactating women: Pregnant women are excluded from this study because the&#xD;
             effects of 68Ga-DOTATATE in pregnancy are not known. Because there is an unknown but&#xD;
             potential risk for adverse events in nursing infants secondary to administration of&#xD;
             68Ga-DOTATATE in the mother, women who are breastfeeding are also excluded from this&#xD;
             study&#xD;
&#xD;
          -  Patients that have recognized concurrent active infection&#xD;
&#xD;
          -  Patients with known hypersensitivity to carbidopa, or who are concurrently taking a&#xD;
             nonselective monoamine oxidase (MAO) inhibitor..&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Smita Jha, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_1991-DK-0085.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>February 7, 2022</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <results_first_submitted>April 6, 2022</results_first_submitted>
  <results_first_submitted_qc>May 12, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2022</results_first_posted>
  <last_update_submitted>May 12, 2022</last_update_submitted>
  <last_update_submitted_qc>May 12, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Genetics</keyword>
  <keyword>Hyperparathyroidism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Multiple Endocrine Neoplasia</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT00001277/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Primary Hyperparathyroidism - Incomplete Data</title>
          <description>Patients with confirmed or suspected primary hyperparathyroidism or complications who are missing age and other baseline data because of changes in data management system</description>
        </group>
        <group group_id="P2">
          <title>Primary Hyperparathyroidism</title>
          <description>Patients with confirmed or suspected primary hyperparathyroidism or complications</description>
        </group>
        <group group_id="P3">
          <title>DOTATATE and F-DOPA</title>
          <description>Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA&#xD;
68Ga-Dotatate: 68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.&#xD;
18F-DOPA: 18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="634"/>
                <participants group_id="P2" count="900"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="634"/>
                <participants group_id="P2" count="900"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>The tracer F-DOPA did not meet Quality Control Standards</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Age is not available for 634 participants in the primary hyperparathyroidism arm because the necessary records are not in the current computer system</population>
      <group_list>
        <group group_id="B1">
          <title>Primary Hyperparathyroidism - Incomplete Data</title>
          <description>Patients with confirmed or suspected primary hyperparathyroidism or complications who are missing age and other baseline data because of changes in data management system</description>
        </group>
        <group group_id="B2">
          <title>Primary Hyperparathyroidism</title>
          <description>Patients with confirmed or suspected primary hyperparathyroidism or complications</description>
        </group>
        <group group_id="B3">
          <title>DOTATATE and F-DOPA</title>
          <description>Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA&#xD;
68Ga-Dotatate: 68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.&#xD;
18F-DOPA: 18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="634"/>
            <count group_id="B2" value="900"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="1553"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>These data are not available because of changes to the data management system. Most were enrolled before the year 2000.</population>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="900"/>
                    <count group_id="B3" value="19"/>
                    <count group_id="B4" value="919"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="48" lower_limit="36" upper_limit="60"/>
                    <measurement group_id="B3" value="54" lower_limit="38" upper_limit="64"/>
                    <measurement group_id="B4" value="48" lower_limit="36" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="634"/>
                    <count group_id="B2" value="900"/>
                    <count group_id="B3" value="19"/>
                    <count group_id="B4" value="1553"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="409"/>
                    <measurement group_id="B2" value="582"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="997"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="318"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="634"/>
                    <count group_id="B2" value="900"/>
                    <count group_id="B3" value="19"/>
                    <count group_id="B4" value="1553"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="634"/>
                    <measurement group_id="B2" value="900"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="634"/>
                    <count group_id="B2" value="900"/>
                    <count group_id="B3" value="19"/>
                    <count group_id="B4" value="1553"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="719"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="735"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="634"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="634"/>
                    <count group_id="B2" value="900"/>
                    <count group_id="B3" value="19"/>
                    <count group_id="B4" value="1553"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="634"/>
                    <measurement group_id="B2" value="900"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="1553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Type of Hyperparathyroidism</title>
        <description>The purpose of this study is to understand the causes of primary hyperparathyroidism, to evaluate and improve methods for diagnosis and treatment, and to provide insight into the mechanisms of normal parathyroid function. Hereditary causes of primary hyperparathyroidism will be characterized. Patients were categorized as follows:&#xD;
MEN1: Diagnosed by demonstration of a germline variant in MEN1 gene or one of the following: a) two of three primary MEN1 manifestations b) one primary MEN1 manifestation with a family member with MEN1.&#xD;
Other familial: Non-MEN1 patients who had a positive family history of hyperparathyroidism suspicious for underlying germline predisposition syndrome.&#xD;
Sporadic: Patients who did not have a positive family history of hyperparathyroidism.&#xD;
Unknown: No data to help categorize the patients in any of the above categories.</description>
        <time_frame>First year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Primary Hyperparathyroidism - Incomplete Data</title>
            <description>Patients with confirmed or suspected primary hyperparathyroidism or complications who are missing age and other baseline data because of changes in data management system</description>
          </group>
          <group group_id="O2">
            <title>Primary Hyperparathyroidism</title>
            <description>Patients with confirmed or suspected primary hyperparathyroidism or complications</description>
          </group>
          <group group_id="O3">
            <title>DOTATATE and F-DOPA</title>
            <description>Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA&#xD;
68Ga-Dotatate: 68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.&#xD;
18F-DOPA: 18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.</description>
          </group>
        </group_list>
        <measure>
          <title>Type of Hyperparathyroidism</title>
          <description>The purpose of this study is to understand the causes of primary hyperparathyroidism, to evaluate and improve methods for diagnosis and treatment, and to provide insight into the mechanisms of normal parathyroid function. Hereditary causes of primary hyperparathyroidism will be characterized. Patients were categorized as follows:&#xD;
MEN1: Diagnosed by demonstration of a germline variant in MEN1 gene or one of the following: a) two of three primary MEN1 manifestations b) one primary MEN1 manifestation with a family member with MEN1.&#xD;
Other familial: Non-MEN1 patients who had a positive family history of hyperparathyroidism suspicious for underlying germline predisposition syndrome.&#xD;
Sporadic: Patients who did not have a positive family history of hyperparathyroidism.&#xD;
Unknown: No data to help categorize the patients in any of the above categories.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="634"/>
                <count group_id="O2" value="900"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>MEN1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="276"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other familial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sporadic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="456"/>
                    <measurement group_id="O2" value="419"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown - insufficient information</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Organs With Identified Lesions</title>
        <description>For each organ, agreement between 68Ga-DOTATATE and 18F-DOPA</description>
        <time_frame>Days 1-6</time_frame>
        <population>Imaging was only conducted in the &quot;DOTATATE and F-DOPA&quot; Arm/Group and therefore results are only reported for this arm</population>
        <group_list>
          <group group_id="O1">
            <title>DOTATATE and F-DOPA</title>
            <description>Patients who received both DOTATATE and F-DOPA scans</description>
          </group>
        </group_list>
        <measure>
          <title>Organs With Identified Lesions</title>
          <description>For each organ, agreement between 68Ga-DOTATATE and 18F-DOPA</description>
          <population>Imaging was only conducted in the &quot;DOTATATE and F-DOPA&quot; Arm/Group and therefore results are only reported for this arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All locations</title>
              <category_list>
                <category>
                  <title>No lesions by Dotatate or F-DOPA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by F-DOPA only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Dotatate only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <title>No lesions by Dotatate or F-DOPA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by F-DOPA only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Dotatate only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <title>No lesions by Dotatate or F-DOPA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by F-DOPA only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Dotatate only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas</title>
              <category_list>
                <category>
                  <title>No lesions by Dotatate or F-DOPA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by F-DOPA only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Dotatate only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duodenum</title>
              <category_list>
                <category>
                  <title>No lesions by Dotatate or F-DOPA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by F-DOPA only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Dotatate only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <title>No lesions by Dotatate or F-DOPA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by F-DOPA only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Dotatate only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adrenal</title>
              <category_list>
                <category>
                  <title>No lesions by Dotatate or F-DOPA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by F-DOPA only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Dotatate only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph nodes</title>
              <category_list>
                <category>
                  <title>No lesions by Dotatate or F-DOPA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by F-DOPA only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Dotatate only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Lesions Identified</title>
        <description>The total number of lesions identified by each imaging modality</description>
        <time_frame>Days 1-6</time_frame>
        <population>Imaging was only conducted in the &quot;DOTATATE and F-DOPA&quot; Arm/Group and therefore results are only reported for this arm. This outcome is only reported for the 16 patients who had both scans</population>
        <group_list>
          <group group_id="O1">
            <title>DOTATATE and F-DOPA</title>
            <description>Patients who received both DOTATATE and F-DOPA scans</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lesions Identified</title>
          <description>The total number of lesions identified by each imaging modality</description>
          <population>Imaging was only conducted in the &quot;DOTATATE and F-DOPA&quot; Arm/Group and therefore results are only reported for this arm. This outcome is only reported for the 16 patients who had both scans</population>
          <units>Lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No lesions by Dotatate or F-DOPA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by F-DOPA only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Dotatate only</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lesions by Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Primary Hyperparathyroidism - Incomplete Data</title>
          <description>Patients with confirmed or suspected primary hyperparathyroidism or complications who are missing age and other baseline data because of changes in data management system</description>
        </group>
        <group group_id="E2">
          <title>Primary Hyperparathyroidism</title>
          <description>Patients with confirmed or suspected primary hyperparathyroidism or complications</description>
        </group>
        <group group_id="E3">
          <title>DOTATATE and F-DOPA</title>
          <description>Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA&#xD;
68Ga-Dotatate: 68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.&#xD;
18F-DOPA: 18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="900"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="900"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="900"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_at_risk="634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="900"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Smita Jha</name_or_title>
      <organization>NIDDK</organization>
      <phone>301-827-1930</phone>
      <email>smita.jha@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

